StreetInsider.com News Articles

Form 6-K Aptorum Group Ltd For: Mar 06

Fri, 06 Mar 2026 16:31:00 +0000

si-local-file:///var/storage/secattach/20260306/26125988.html

Form 6-K Aptorum Group Ltd For: Mar 06

Fri, 06 Mar 2026 16:31:00 +0000

si-local-file:///var/storage/secattach/20260306/26125988.html

Aptorum Group receives Nasdaq deficiency notice for $1 minimum bid price

Fri, 06 Mar 2026 16:30:06 +0000

Aptorum Group Limited (NASDAQ: APM) received a notification from Nasdaq Stock Market LLC on March 5 regarding non-compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2).

The notification does not immediately impact the listing or trading of the company's shares on Nasdaq. Aptorum has been granted a 180-calendar-day grace period until September 1, 2026, to regain compliance with the listing requirement.

The pharmaceutical company stated it intends to evaluate all available options to restore compliance during this period, including a potential reverse stock split if necessary. Aptorum said it remains committed to maintaining its Nasdaq

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Fri, 06 Mar 2026 16:30:00 +0000

Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).

The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement.

During this period,

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Fri, 06 Mar 2026 16:30:00 +0000

During this period,

Form 6-K Aptorum Group Ltd For: Feb 06

Fri, 06 Feb 2026 16:00:00 +0000

si-local-file:///var/storage/secattach/20260206/25961361.html

Form 6-K Aptorum Group Ltd For: Feb 06

Fri, 06 Feb 2026 16:00:00 +0000

si-local-file:///var/storage/secattach/20260206/25961361.html

DiamiR and INB collaborate to validate APOE testing platform

Mon, 02 Feb 2026 08:03:50 +0000

Aptorum Group Limited (NASDAQ: APM) announced that DiamiR Biosciences Corp. and Instant NanoBiosensors Co., Ltd. have entered into a collaboration to validate INB's automated APOE testing platform for clinical use in DiamiR's laboratory.

DiamiR will compare INB's automated G8 Genotyping Analyzer for APOE testing with its New York State approved APOE test. The project will evaluate INB's platform performance and its suitability as a clinical solution for Alzheimer's disease testing within DiamiR's CLIA-certified, CAP-accredited laboratory.

The APOE gene represents the strongest known genetic risk factor for late-onset Alzheimer's disease. Individuals carrying one copy of the APOE ε4 allele have approximately 2-4 times

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease

Mon, 02 Feb 2026 08:00:00 +0000

NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB’s automated APOE testing platform

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease

Mon, 02 Feb 2026 08:00:00 +0000

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease

Mon, 02 Feb 2026 08:00:00 +0000

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease

Mon, 02 Feb 2026 08:00:00 +0000